Login to Your Account



Other News To Note


Thursday, February 28, 2013

• Titan Pharmaceuticals Inc., of South San Francisco, said the FDA's Psychopharmacologic Drugs Advisory Committee is scheduled to review the firm's new drug application (NDA) for Probuphine for the maintenance treatment of adults with opioid dependence on March 21.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription